@article{ATM21864,
author = {Shinkyo Yoon and Chang Min Choi and Jae Cheol Lee},
title = {The different path of T790M-positive EGFR-mutant lung cancer},
journal = {Annals of Translational Medicine},
volume = {6},
number = {Suppl 1},
year = {2018},
keywords = {},
abstract = {Approximately half of the cases of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are mediated by the secondary T790M mutation (1,2). Distinct clinical course of patients with T790M-positive lung cancer has been suggested, mostly in the context of more indolent progression and favorable prognosis (3,4). It is in line with the pre-clinical study showing that EGFR-mutant cell lines with acquired T790M mutation exhibit slower growth although the way how the additional T790M mutation can affect the growth rate of EGFR-mutant lung cancer cells remains unclear (5).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/21864}
}